Updating results

436 results

Sort: Relevance | Date

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

In development [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance In development

Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

In development [GID-TA10567] Expected publication date: 24 November 2021

Technology appraisal guidance In development

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

In development [GID-TA10387] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

In development [GID-TA10420] Expected publication date: 23 June 2021

Technology appraisal guidance In development

Liraglutide for managing overweight and obesity [ID740]

In development [GID-TA10388] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [ID3754]

In development [GID-TA10621] Expected publication date: 25 March 2020

Technology appraisal guidance In development

Niraparib for maintenance treatment of platinum-sensitive ovarian, fallopian tube and peritoneal cancer after response to 1 course of platinum-based chemotherapy [ID1680]

In development [GID-TA10551] Expected publication date: 03 February 2021

Technology appraisal guidance In development

Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: TBC

Technology appraisal guidance In development

Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer [ID1338]

In development [GID-TA10317] Expected publication date: TBC

Technology appraisal guidance In development

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]

In development [GID-TA10510] Expected publication date: TBC

Technology appraisal guidance In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]

In development [GID-TA10565] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

In development [GID-TA10389] Expected publication date: TBC

Technology appraisal guidance In development

Esketamine for treatment-resistant depression (ID1414)

In development [GID-TA10371] Expected publication date: TBC

Technology appraisal guidance In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]

In development [GID-TA10398] Expected publication date: 03 February 2021

Technology appraisal guidance In development

Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

In development [GID-TA10623] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for maintenance treatment of advanced urothelial cancer after platinum-based chemotherapy [ID3735]

In development [GID-TA10624] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID1504]

In development [GID-TA10400] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: 15 December 2021

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: 11 August 2020

Technology appraisal guidance In development

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]

In development [GID-TA10331] Expected publication date: TBC

Technology appraisal guidance In development

Trifluridineā€“tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]

In development [GID-TA10456] Expected publication date: TBC

Technology appraisal guidance In development

Galcanezumab for preventing migraine [ID1372]

In development [GID-TA10454] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide with rituximab for previously treated follicular lymphoma [ID1374]

In development [GID-TA10323] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]

In development [GID-TA10222] Expected publication date: 13 January 2021

Technology appraisal guidance In development

KTE-X19 for treating relapsed or refractory mantle cell lymphoma [ID1313]

In development [GID-TA10312] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Technology appraisal guidance In development

Systemic lupus erythematosus - prasterone [ID392]

In development [GID-TAG373] Expected publication date: TBC

Technology appraisal guidance In development

Falls - faller's clinics [ID103]

In development [GID-TAG375] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]

In development [GID-TAG436] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell) - cetuximab [ID9]

In development [GID-TAG395] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (prevention) - rivaroxaban [ID463]

In development [GID-TAG427] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]

In development [GID-TAG337] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute) - serelaxin [ID673]

In development [GID-TAG454] Expected publication date: TBC

Technology appraisal guidance In development

Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

In development [GID-TAG332] Expected publication date: TBC

Technology appraisal guidance In development

Macular oedema (diabetic) - pegaptanib sodium [ID452]

In development [GID-TAG280] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]

In development [GID-TAG528] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - abatacept [ID27]

In development [GID-TAG402] Expected publication date: TBC

Technology appraisal guidance In development

Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Technology appraisal guidance In development

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

In development [GID-TAG360] Expected publication date: TBC

Technology appraisal guidance In development